BIXT — BIOXYTRAN, INC
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1445815 ·
Last close
$0.02
Market Cap
$2.42M
52W High
$0.09
52W Low
$0.02
ADV30
120,269
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -660,180 | -619,929 | 333,393 | 177,384 | 5,274,697 |
| Mar 2026 | 0 | — | -1,935,161 | -2,068,989 | 615,253 | 463,047 | 5,010,121 |
| Dec 2025 | 0 | — | -610,232 | -522,155 | 658,552 | 509,914 | 3,249,894 |
| Sep 2025 | 0 | — | -500,241 | -282,726 | 156,294 | 14,499 | 3,060,937 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-597,742
Investing CF
$-32,303
Financing CF
$1,088,744
CapEx
$-32,303
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.04
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-23,113,235
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-2,623,441
Pretax Income TTM
$-2,838,433
Interest Exp TTM
$214,992
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,854,053 | -2,123,077 | 658,552 | 3,249,894 | -2,591,342 | -526,455 |
| Dec 2024 | 0 | -2,231,018 | -2,366,681 | 138,694 | 1,930,642 | -1,791,948 | -381,316 |
| Dec 2023 | 0 | -3,808,497 | -4,472,525 | 139,382 | 3,244,238 | -2,423,970 | -775,375 |
| Dec 2022 | 0 | -2,440,185 | -2,473,134 | 370,936 | 3,667,911 | -2,706,347 | -1,803,670 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PPBT | PURPLE BIOTECH LTD. | $2.42M | $1.49 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $2.40M | $4.11 | — |
| VBIO | Valion Bio, Inc. | $2.40M | $2.70 | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $2.36M | $4.30 | — |
| GNPX | Genprex, Inc. | $2.30M | $2.81 | — |
News headlines (Yahoo Finance, 1h cache)
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial
2026-08-11 11:00 · Yahoo
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
2026-05-29 12:03 · Yahoo
Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs
2026-08-04 11:00 · Yahoo
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
2026-07-29 11:00 · Yahoo
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
2026-03-20 13:05 · Yahoo
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
2026-03-04 20:40 · Yahoo
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
2026-03-02 16:40 · Yahoo
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
2025-12-10 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.